Ángel Lucio is CEO of Tetraneuron, a Spanish biotech company developing gene therapies to modify and potentially reverse Alzheimer’s disease. With over 17 years of international leadership at Johnson & Johnson, Takeda, Reckitt and Sanofi, he has held senior roles across Europe and Asia, with a track record in driving growth through business development, neuroscience strategy and international leadership. He now leverages this global experience to lead Tetraneuron’s mission of delivering transformative therapies in neurodegeneration.